Regencell Bioscience Holdings Ltd

Regencell Bioscience Holdings Ltd (RGC) priced its initial public offering on Jul 20, 2021 at $9.50 per share, raising $21.9M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $120.1M. Maxim Group was lead-left underwriter. Ogier and Hunter Taubman Fischer & Li advised the company and Loeb & Loeb advised the underwriters.

Regencell Bioscience Holdings Ltd is an early-stage bioscience company that began in Hong Kong in 2014. It researches, develops and commercializes traditional Chinese medicine to treat neurocognitive disorders, specifically attention deficit hyperactivity disorder and autism spectrum disorder in children.

Status

IPO

Ticker

RGC

Exchange

Nasdaq Capital Market

Priced

Jul 20, 2021

IPO price

$9.50

Raised

$21.9M

Market cap at IPO price

$120.1M

First filed

Mar 22, 2021

Underwriters

Maxim Group

Company counsel

Ogier and Hunter Taubman Fischer & Li

Underwriters' counsel

Loeb & Loeb

Sector

Biotech & pharma

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.